Q-Centrix, LLC

Q-Centrix, LLC is a healthcare analytics company that specializes in clinical data management. They provide innovative solutions to enhance patient care and optimize operational efficiency. Founded in 2010 and headquartered in Portsmouth, US, Q-Centrix, LLC focuses on transforming clinical data into actionable insights. The company has engaged in three deals to date.

Milton Silva-Craig serves as the CEO, steering the company through its growth and ensuring effective leadership. Recently, in June 2025, Q-Centrix was acquired by MRO Corp. , a portfolio company of Parthenon Capital. Q-Centrix specializes in healthcare analytics and clinical data management, offering a suite of advanced data management solutions designed to optimize performance, enhance patient care, and streamline operational processes.

Their core product, the eCDM™ platform, enables healthcare systems to convert fragmented clinical data into structured, actionable insights, facilitating improved decision-making and operational efficiency. The company targets hospitals and health systems, providing services such as tailored data sets, expert chart reviews, and patient screening, which collectively address challenges in quality measurement, research, and overall clinical performance. Q-Centrix's offerings have been particularly beneficial in U. S.

markets, where their clients include major healthcare institutions seeking to unlock data potential and drive better health outcomes through evidence-based insights. Q-Centrix operates on a business-to-business (B2B) transactional model, with revenue generated primarily through partnerships and subscriptions to their eCDM™ platform and associated services. The firm engages with health systems and hospitals, delivering tailored solutions that enhance clinical data management. Clients typically enter into contractual agreements that outline service deliverables and performance metrics, ensuring alignment with healthcare objectives.

The pricing structure is designed to reflect the complexity and scope of services provided, with flagship offerings such as the eCDM™ platform at the forefront. This structured approach to revenue generation allows Q-Centrix to create long-term relationships with healthcare providers, fostering ongoing collaboration in clinical improvement initiatives and research advancements. The recent acquisition by MRO Corp. in June 2025 positions Q-Centrix for future growth by enabling the advancement of its healthcare platform.

This strategic move is anticipated to expand its offerings and market reach, facilitating the design and launch of new products. Q-Centrix is expected to target new geographical markets to enhance its service delivery and broaden its client base. Additional resources from the acquisition will likely bolster these initiatives, allowing for a more comprehensive integration into healthcare systems and enhancing the overall capabilities of their eCDM™ solutions.